An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 019599
Company: LEGACY PHARMA

Products on NDA 019599

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
NAFTIN	NAFTIFINE HYDROCHLORIDE	1% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CREAM;TOPICAL	Discontinued	None	Yes	No
NAFTIN	NAFTIFINE HYDROCHLORIDE	2%	CREAM;TOPICAL	Prescription	AB	Yes	Yes

Approval Date(s) and History, Letters, Labels, Reviews for NDA 019599

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
02/29/1988	ORIG-1	Approval	Type 1 - New Molecular Entity	STANDARD		Label is not available on this site.

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
04/30/2018	SUPPL-14	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019356s008,019599s014,204286s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/019356Orig1s008,019599Orig1s014,204286Orig1s003ltr.pdf
11/10/2016	SUPPL-13	Efficacy-New Patient Population	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019599s013lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/019599Orig1s013ltr.pdf
10/10/2014	SUPPL-12	Efficacy-New Patient Population	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019599s012lbledt.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/019599Orig1s012ltr.pdf
01/13/2012	SUPPL-11	Efficacy-New Dosing Regimen	Label (PDF) Letter (PDF) Review (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019599s011lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/019599s011ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/019599Orig1s011.pdf
01/26/2009	SUPPL-10	Labeling-Package Insert	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/019599s010ltr.pdf
08/10/2006	SUPPL-9	Labeling-Container/Carton Labels, Labeling-Package Insert		Label is not available on this site.
06/04/2002	SUPPL-7	Manufacturing (CMC)	Review (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/019599Orig1s007.pdf
11/30/1998	SUPPL-6	Manufacturing (CMC)		Label is not available on this site.
09/24/1997	SUPPL-5	Manufacturing (CMC)-Control		Label is not available on this site.
06/15/1995	SUPPL-4	Manufacturing (CMC)-Packaging		Label is not available on this site.
01/30/1990	SUPPL-3	Manufacturing (CMC)-Control		Label is not available on this site.
07/05/1990	SUPPL-2	Efficacy-New Dosing Regimen		Label is not available on this site.
04/05/1989	SUPPL-1	Efficacy-New Indication		Label is not available on this site.

Labels for NDA 019599

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
04/30/2018	SUPPL-14	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019356s008,019599s014,204286s003lbl.pdf
11/10/2016	SUPPL-13	Efficacy-New Patient Population	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019599s013lbl.pdf
10/10/2014	SUPPL-12	Efficacy-New Patient Population	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019599s012lbledt.pdf
01/13/2012	SUPPL-11	Efficacy-New Dosing Regimen	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019599s011lbl.pdf

Therapeutic Equivalents for NDA 019599

NAFTIN

CREAM;TOPICAL; 2%
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
NAFTIFINE HYDROCHLORIDE	NAFTIFINE HYDROCHLORIDE	2%	CREAM;TOPICAL	Prescription	No	AB	206960	AMNEAL
NAFTIFINE HYDROCHLORIDE	NAFTIFINE HYDROCHLORIDE	2%	CREAM;TOPICAL	Prescription	No	AB	206901	TARO
NAFTIFINE HYDROCHLORIDE	NAFTIFINE HYDROCHLORIDE	2%	CREAM;TOPICAL	Prescription	No	AB	210038	XIROMED
NAFTIN	NAFTIFINE HYDROCHLORIDE	2%	CREAM;TOPICAL	Prescription	Yes	AB	019599	LEGACY PHARMA

Top